Aura Biosciences
AURA
34 hedge funds and large institutions have $299M invested in Aura Biosciences in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
36% more capital invested
Capital invested by funds: $220M → $299M (+$78.6M)
6% more funds holding
Funds holding: 32 → 34 (+2)
2.11% more ownership
Funds ownership: 44.78% → 46.9% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.86M |
| 2 |
Barclays
London,
United Kingdom
|
+$1.14M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$791K |
| 4 |
State Street
Boston,
Massachusetts
|
+$720K |
| 5 |
BlackRock
New York
|
+$690K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$170K |
| 2 |
JP Morgan Chase
New York
|
-$75.6K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$66K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$39K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$36.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $24K | +$8.59K | +451 | +69% |
|
27
Morgan Stanley
New York
| $24K | +$11K | +575 | +108% |
|
|
28
UBS Group
Zurich,
Switzerland
| $17K | -$36.1K | -1,893 | -72% |
|
|
AB
29
Amalgamated Bank
New York
| $17K | +$15.1K | +791 | New |
|
|
AF
30
Amalgamated Financial
New York
| $17K | +$15.1K | +791 | New |
|
31
Legal & General Group
London,
United Kingdom
| $11K | – | – | – |
|
|
AIP
32
Ameritas Investment Partners
Lincoln,
Nebraska
| $9K | – | – | – |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | -$15.5K | -813 | -70% |
|
34
Citigroup
New York
| $5K | -$30.2K | -1,586 | -88% |
|
|
CCM
35
CAAS Capital Management
New York
| – | -$170K | -10,000 | Closed |
|
|
36
Marshall Wace
London,
United Kingdom
| – | -$66K | -3,886 | Closed |
|
|
CWP
37
Concord Wealth Partners
Abingdon,
Virginia
| – | -$3K | -150 | Closed |
|
AURA Hedge Fund Activity: Q1 2022 in Review
34 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q1 2022, worth a combined $299M — up 36% from $220M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AURA positions and 3 closed out — a net gain of 2 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $3.86M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $170K sold.
- 34 institutional investors held Aura Biosciences (AURA) as of Q1 2022, up from 32 in Q4 2021.
- Funds reported $299M of Aura Biosciences stock for Q1 2022, up 36% quarter-over-quarter.
- 5 funds opened new Aura Biosciences positions in Q1 2022 and 3 closed out, a net change of +2 holders.
- The largest Aura Biosciences buyer in Q1 2022 was Nantahala Capital Management, an estimated $3.86M added.
- The largest Aura Biosciences seller in Q1 2022 was CAAS Capital Management, an estimated $170K sold.
Based on aggregated 13F filings for Q1 2022.